Compare RUN & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RUN | OCUL |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.4B |
| IPO Year | 2015 | 2014 |
| Metric | RUN | OCUL |
|---|---|---|
| Price | $17.91 | $14.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 10 |
| Target Price | $20.63 | ★ $22.56 |
| AVG Volume (30 Days) | ★ 7.1M | 3.8M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,316,656,000.00 | $55,783,000.00 |
| Revenue This Year | $18.66 | N/A |
| Revenue Next Year | $6.33 | $14.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.79 | N/A |
| 52 Week Low | $5.38 | $5.79 |
| 52 Week High | $22.44 | $16.44 |
| Indicator | RUN | OCUL |
|---|---|---|
| Relative Strength Index (RSI) | 46.24 | 63.98 |
| Support Level | $17.47 | $11.15 |
| Resistance Level | $18.91 | $16.44 |
| Average True Range (ATR) | 1.02 | 0.77 |
| MACD | -0.01 | 0.32 |
| Stochastic Oscillator | 20.10 | 65.72 |
Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.